Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Novel immunologic therapies.

Leslie C Grammer1

  • 1Division of Allergy/Immunology, Department of Medicine, Northwestern University, Chicago, Illinois, USA.

Allergy and Asthma Proceedings
|January 17, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Heterogeneity and clinical relevance of group 2 innate lymphoid cells subsets in nasal polyps.

The Journal of allergy and clinical immunology·2026
Same author

The Association Between Sinus Surgery and the Development of Asthma and Non-Cystic Fibrosis Bronchiectasis in Patients With Chronic Rhinosinusitis.

International forum of allergy & rhinology·2025
Same author

Effects of type 3 and neutrophilic inflammation on type 2 chronic rhinosinusitis with nasal polyps.

The Journal of allergy and clinical immunology·2025
Same author

Tezepelumab inhibits highly functional truncated thymic stromal lymphopoietin in chronic rhinosinusitis.

The Journal of allergy and clinical immunology·2025
Same author

Analysis of human neutrophils from nasal polyps by single-cell RNA sequencing reveals roles of neutrophils in chronic rhinosinusitis.

The Journal of allergy and clinical immunology·2024
Same author

Associations Between Chronic Rhinosinusitis and the Development of Non-Cystic Fibrosis Bronchiectasis.

The journal of allergy and clinical immunology. In practice·2024
Same journal

Key factors in the diagnosis of sesame allergy in children.

Allergy and asthma proceedings·2026
Same journal

Immunoglobulin E-mediated pumpkin seed allergy in children: Case series and narrative review with a structured literature search.

Allergy and asthma proceedings·2026
Same journal

Predictors of delayed treatment-free remission with omalizumab in chronic spontaneous urticaria.

Allergy and asthma proceedings·2026
Same journal

The digital front door: A national analysis of U.S. allergy and immunology fellowship program web sites.

Allergy and asthma proceedings·2026
Same journal

The impact of dietary patterns on the risk of asthma in children.

Allergy and asthma proceedings·2026
Same journal

The alpha-gal syndrome: Understanding the role of tick bites, and the delays in severe anaphylaxis.

Allergy and asthma proceedings·2026
See all related articles

Current allergen immunotherapy effectively treats allergic inflammation but has drawbacks. Novel therapies aim to block key allergic cascade factors or modify immunotherapy delivery for safer, faster treatments.

Area of Science:

  • Immunology
  • Allergy Research
  • Pharmacology

Background:

  • Allergen immunotherapy is a current standard for allergic inflammation treatment.
  • Existing immunotherapy is time-consuming and poses risks, including anaphylaxis.

Purpose of the Study:

  • To explore novel therapeutic strategies for allergic inflammation.
  • To identify alternative approaches beyond current immunotherapy limitations.

Main Methods:

  • Investigating methods to block key factors in the allergic cascade.
  • Exploring modifications to current immunotherapy administration protocols.

Main Results:

  • Two primary novel therapeutic avenues were identified.
  • One approach focuses on targeted blockade within the allergic pathway.

Related Experiment Videos

  • The second approach centers on optimizing immunotherapy delivery.

    • Conclusions:

    • Novel therapies offer potential improvements over current allergen immunotherapy.
    • Future treatments may involve blocking specific allergic mediators or enhancing immunotherapy delivery for improved safety and efficiency.